Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount data on the safety and efficacy of novel agents such as CCR5 inhibitors, entry inhibitors, and integrase inhibitors as therapy for treatment-experienced or treatment-naive HIV patients
- Summarize new data on the use of novel therapies in the setting of resistant HIV
- Describe the in vitro activity of novel therapies in the HIV setting, including novel PIs and fusion inhibitors
Topics covered include:
- Maraviroc in Patients With Dual/Mixed R5/X4 Virus
- Vicriviroc in R5-Tropic Treatment-Experienced Patients
- Virologic Benefit With Entry Inhibitor TNX-355 in Treatment-Experienced HIV-Infected Patients
- Novel PIs Demonstrate Potent in Vitro Activity Against Drug-Resistant HIV
- Fosalvudine Tidoxil Safe and Tolerable in Single-Dose Study in HIV-Infected Patients
- Integrase Inhibitor MK-0518 Shows Potent Activity in Treatment-Naive HIV-Infected Adults